Efficacy of splenectomy for hypersplenic patients with advanced hepatocellular carcinoma

Hepatology Research

Volumn 38, Issue 12, 2008, Pages 1172-1177

  Hirooka, Masashi ^a   Ishida, Kiyotaka ^a   Kisaka, Yoshiyasu ^a   Uehara, Takahide ^a   Watanabe, Yuji ^a   Hiasa, Yoichi ^a   Michitaka, Kojiro ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Splenectomy

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; HYPERSPLENISM; LAPAROSCOPIC SURGERY; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SPLENECTOMY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 55449114044     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00389.x     Document Type: Article

References (20)

1. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
2. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Int Med 1999; 131: 174-81.
3. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
4. Torzilli G, Makuuchi M, Inoue K et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: Is there a way? A prospective analysis of our approach. Arch Surg 1999; 134: 984-92.
5. Sugawara Y, Yamamoto J, Shimada K et al. Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg 2000; 190: 446-50.
6. Bolognesi M, Merkel C, Sacerdoti D, Nava V, Gatta A. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 2002; 34: 144-50.
7. Piscaglia F, Zironi G, Gaiani S et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. Hepatology 1999; 30: 58-64.
8. Tomikawa M, Hashizume M, Akahoshi T et al. Effect of splenectomy on liver volume and prognosis of cirrhosis in patients with esophageal varices. J Gastroenterol Hepatol 2002; 17: 77-80.
9. Cao ZX, Chen XP, Wu ZD. Effects of splenectomy in patients with cirrhosis undergoing hepatic resection for hepatocellular carcinoma. World J Gastroenterol 2003; 9: 2460-3.
10. Chen XP, Wu ZD, Huang ZY, Qiu FZ. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg 2005; 92: 334-9.
11. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-6.
12. Yamasaki T, Kurokawa F, Shirahashi H et al. Novel arterial infusion chemotherapy using cisplatin, 5 -fluorouracil, and leucovorin for patients for patients with advanced hepatocellular carcinoma. Hepatol Res 2002; 23: 7-17.
13. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
14. Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer, 1st edn. Tokyo: Kanehara, 1997.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
16. Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 2004; 57: 358-65.
17. Park JO, Lee SI, Song SY et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003; 33: 533-7.
18. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 3: 176-81.
19. Hirai K, Kawazoe Y, Yamashita K et al. Transcatheter partial splenic arterial embolization in patients with hypersplenism: A clinical evaluation as supporting therapy for hepatocellular carcinoma and liver cirrhosis. Hepatogastroenterology 1986; 33: 105-8.
20. Sangro B, Bilbao I, Herrero I et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 1993; 18: 309-14.